Adrian et al compared the relationship between targetable genomic alterations and age in 2237 patients with lung cancer and found that young patients had higher frequencies of EGFR, ALK, ROS1, and ERBB2 alterations [9]. The gene discussed is ERBB2; the disease is lung cancer.